Patents by Inventor Lewis J. Rubin
Lewis J. Rubin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230062605Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: October 17, 2022Publication date: March 2, 2023Applicant: United Therapeutics CorporationInventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
-
Publication number: 20220323459Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: May 16, 2022Publication date: October 13, 2022Applicant: United Therapeutics CorporationInventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
-
Publication number: 20220218720Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: March 29, 2022Publication date: July 14, 2022Applicant: United Therapeutics CorporationInventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
-
Patent number: 11357782Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: GrantFiled: September 27, 2021Date of Patent: June 14, 2022Assignee: United Therapeutics CorporationInventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
-
Publication number: 20220008436Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: September 27, 2021Publication date: January 13, 2022Applicant: United Therapeutics CorporationInventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
-
Patent number: 11154210Abstract: A method for treating pulmonary arterial hypertension in a patient can include determining whether a patient with pulmonary arterial hypertension has an enlarged right ventricle or right ventricular dysfunction, where the patient has previously been administered a prostanoid and weaning the patient off of the prostanoid if the patient does not have an enlarged right ventricle or right ventricular dysfunction.Type: GrantFiled: January 7, 2013Date of Patent: October 26, 2021Assignee: VERO Biotech LLCInventors: Tammy Watts, Robert F. Roscigno, David H. Fine, Lewis J. Rubin
-
Patent number: 10716793Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: GrantFiled: January 31, 2020Date of Patent: July 21, 2020Assignee: United Therapeutics CorporationInventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
-
Publication number: 20200171044Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: January 31, 2020Publication date: June 4, 2020Applicant: United Therapeutics CorporationInventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas Schmehl, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
-
Publication number: 20190365778Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: August 9, 2019Publication date: December 5, 2019Applicant: United Therapeutics CorporationInventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
-
Patent number: 10376525Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: GrantFiled: February 1, 2016Date of Patent: August 13, 2019Assignee: United Therapeutics CorporationInventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
-
Patent number: 9358240Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: GrantFiled: November 12, 2009Date of Patent: June 7, 2016Assignee: United Therapeutics CorporationInventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
-
Publication number: 20160143868Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: February 1, 2016Publication date: May 26, 2016Applicant: United Therapeutics CorporationInventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
-
Patent number: 9339507Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: GrantFiled: May 11, 2012Date of Patent: May 17, 2016Assignee: United Therapeutics CorporationInventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
-
Patent number: 8969409Abstract: One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration.Type: GrantFiled: May 22, 2013Date of Patent: March 3, 2015Assignee: United Therapeutics CorporationInventors: Martine A. Rothblatt, Lewis J. Rubin
-
Patent number: 8609728Abstract: One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration.Type: GrantFiled: March 14, 2011Date of Patent: December 17, 2013Assignee: United Therapeutics CorporationInventors: Martine A. Rothblatt, Lewis J. Rubin
-
Publication number: 20130253049Abstract: One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration.Type: ApplicationFiled: May 22, 2013Publication date: September 26, 2013Applicant: United Therapeutics CorporationInventors: Martine A. Rothblatt, Lewis J. Rubin
-
Publication number: 20120216801Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: May 11, 2012Publication date: August 30, 2012Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
-
Publication number: 20110224236Abstract: One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration.Type: ApplicationFiled: March 14, 2011Publication date: September 15, 2011Inventors: Martine A. Rothblatt, Lewis J. Rubin
-
Patent number: 7964573Abstract: The present invention relates to compositions related to a polynucleotide encoding a transient receptor potential channel gene. Also disclosed is the use of this polynucleotide, its homologs, fragments, variants and its resultant polypeptides in the diagnosis, prevention and treatment of disease, particularly idiopathic pulmonary arterial hypertension (IPAH). This invention also teaches the use of these polynucleotides and polypeptides as assays for drug discovery and therapies.Type: GrantFiled: January 17, 2006Date of Patent: June 21, 2011Assignee: The Regents of the University of CaliforniaInventors: Carmelle Remillard, Lewis J. Rubin, Ying Yu, Jason X.-J. Yuan
-
Publication number: 20100076083Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: November 12, 2009Publication date: March 25, 2010Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel